One of the newest SARMs, Testolone (RAD140) is a selective androgen receptor modulator (SARM) currently under development by Radius Health Inc. The intent of RAD140 is to serve as an alternative to testosterone replacement therapy. In the body, a normal dose of RAD140 mimics the effects of a LARGE DOSE of testosterone in muscle tissue, but expresses minimal affinity for non-muscular tissue. This results in substantially fewer undesirable side effects when compared with traditional anabolic steroids.
As of this writing, RAD140 trials have shown an absence of side-effects normally associated with anabolics. Specifically, estrogen, progesterone, and prolactin-related side effects are ZERO.
Regarding HPG/HPTA suppression: All SARMs will exhibit a degree of suppression, and RAD140 is no exception. The key word here is suppression. Traditional anabolics don’t just suppress, they cause complete shutdown. While some researchers dispute the ratio of LH/FSH/Testosterone suppression caused by SARMs, the bottom line is: SARMs suppress endogenous hormone production to a much lesser degree than traditional anabolics, making recovery MUCH faster. While we don’t necessarily recommend it as an optimal approach, many researchers opt to skip PCT for SARMs-only cycles.
RAD140 is still in Phase 1 of human trials, thus clinical studies on this SARM are few. Initial trials show RAD140 to be extremely effective at increasing athletic endurance, stamina, and speed, as well as strength and muscle volume in a short time frame. Because the product is anabolic in nature, it secondarily functions as a strong anti-catabolic, and will help preserve muscle mass during a caloric deficit / cutting cycle.